



Breast Cancer: Molecular Mechanisms, Diagnosis Techniques and Therapeutic Targets

Guest Editor:

Dr. Shipra Gandhi

Department of Medicine, Roswell
Park Comprehensive Cancer
Center, Buffalo, NY, USA

Deadline for manuscript
submissions:


25 March 2025

Message from the Guest Editor

Breast cancer remains one of the most common cancers affecting women. Its molecular mechanism involves the growth, migration and invasion of cancerous cells due to dysfunctional proteins and pathways at a genetic level. The main subtypes include Luminal A, Luminal B, HER2-enriched and triple-negative breast cancers. Each has different biomarkers and therapeutic responses. Diagnosis techniques include self-examination, mammography, ultrasound, biopsy and genetic testing. These methods help to identify the stage, type and spread of the cancer. The advancements in molecular biology have led to the formation of therapeutic targets such as hormone receptors (estrogen and progesterone receptors), HER2 proteins and BRCA1 and BRCA2 genes. Targeted therapies based on these receptors and genes have shown better results in treatment. Hormone therapy, radiation therapy, chemotherapy, immunotherapy and surgery are some standard treatment options.

This Special Issue aims to present a collection of original research articles and reviews that address the use of modern molecular diagnosis techniques and targeted therapies in breast cancer.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)